Phase 1, randomised, subject-blind, placebo-controlled, partial crossover study of LY2409021 in healthy male subjects.
Phase of Trial: Phase I
Latest Information Update: 23 May 2012
At a glance
- Drugs Adomeglivant (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 23 May 2012 Actual end date (March 2008) added as reported by ClinicalTrials.gov.
- 23 May 2012 Actual initiation date (May 23, 2012) added as reported by ClinicalTrials.gov.
- 23 May 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT01606423).